  Currently, 90 percent of drugs fail in one of the four phases of human trials. AI-based discovery approaches could screen the properties of millions of molecules and protein properties to find the best matches—the ones that are most likely to have a positive impact on understanding complex disease states. |
 |
 |  |
Laboratory Equipment is powered by Labcompare. You are receiving this email because you are subscribed to our database. Need to change your settings?
Email Settings or Unsubscribe here
